Nuo Therapeutics, Inc. (AURX) insider trading
Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 6, 2026.
- Filings shown
- 10
- Open-market buys
- 2
- Open-market sells
- 0
- Buys, 10b5-1 box not checked
- 2 of 2
Counts cover the 10 most recent Form 4 filings Tradune holds for AURX (filed Jun 2 – Oct 6, 2026); the score below covers only the trailing 90 days (0 buys, 0 sells). SEC EDGAR Form 4 filings for AURX last checked Nov 22, 2026, 09:00 UTC; the latest AURX filing Tradune holds was filed Oct 6, 2026. This is not guaranteed to be the complete record — see AURX's full Form 4 filing history on SEC EDGAR.
Open-market activity, last 90 days
Purchases (Form 4 code P) and sales (code S) on the 2 filings Tradune holds for AURX filed Aug 31 – Oct 6, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.
| Insider | Buys | Sells | Shares bought | Shares sold | Value |
|---|---|---|---|---|---|
| David Emerson JordenCEO/CFO | 2 | 0 | 8,773 | — | +$9,539 |
Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.
Insider-activity score
0/ 100
Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →
Get alerted when insiders buy the stocks you own
Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.
Free for everyone right now · no card · nothing to buy
How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).
Insider Buying at AURX
Insiders reported 2 open-market purchases of AURX between Jun 2, 2026 and Oct 6, 2026, across 1 distinct buyer. The most recent purchase was reported by David Emerson Jorden (CEO/CFO) on Aug 28, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Recent Form 4 filings
Source: SEC EDGAR Form 4 · transaction codes explained
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Prepayment Restated Warrant (right to buy) | 458 | $1.50 | — | — | Oct 6, 2026 |
| Grant / award Second Restated Warrant (right to buy) | 4,500 | $1.50 | — | — | Oct 6, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market purchase 10b5-1 box not checked | 7,984 | $1.09 | 2,070,000 | +0.4% | Aug 28, 2026 |
| Open-market purchase 10b5-1 box not checked | 789 | $1.07 | 2,062,016 | +0.0% | Aug 27, 2026 |
† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.
“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise | 162,500 | $1.00 | 2,222,119 | +7.9% | Jun 30, 2026 |
| Option exercise Option to purchase common stock | 162,500 | — | — | — | Jun 30, 2026 |
| Tax withholding | 160,892 | $1.01 | 2,061,227 | −7.2% | Jun 30, 2026 |
| Grant / award Option to purchase common stock | 125,000 | — | — | — | Jun 29, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise Option to purchase common stock | 40,000 | — | — | — | Jun 30, 2026 |
| Tax withholding | 39,604 | $1.01 | 5,400,396 | −0.7% | Jun 30, 2026 |
| Option exercise | 40,000 | $1.00 | 5,440,000 | +0.7% | Jun 30, 2026 |
| Grant / award Option to purchase common stock | 30,000 | — | — | — | Jun 29, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise | 40,000 | $1.00 | 212,654 | +23% | Jun 30, 2026 |
| Tax withholding | 39,604 | $1.01 | 173,050 | −19% | Jun 30, 2026 |
| Option exercise Option to purchase common stock | 40,000 | — | — | — | Jun 30, 2026 |
| Grant / award Option to purchase common stock | 30,000 | — | — | — | Jun 29, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Option to purchase common stock | 65,000 | — | — | — | Jun 29, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Option to Purchase Common Stock | 30,000 | — | — | — | Jun 29, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award | 13,245 | $1.10 | 2,085,000 | +0.6% | Jun 5, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Second Restated Warrant (right to buy) | 17,500 | $1.50 | — | — | May 29, 2026 |
| Disposition to issuer Prepayment Warrant (right to buy) | 7,516 | $1.50 | — | — | May 29, 2026 |
| Grant / award Prepayment Restated Warrant (right to buy) | 7,333 | $1.50 | — | — | May 29, 2026 |
| Disposition to issuer Second Warrant (right to buy) | 36,750 | $1.50 | — | — | May 29, 2026 |
| Grant / award Interim Warrant (right to buy) | 17,450 | $1.50 | — | — | May 29, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Initial Warrant (right to buy) | 30,050 | $1.50 | — | — | Jan 23, 2026 |
| Grant / award Second Warrant (right to buy) | 36,750 | $1.50 | — | — | Jan 23, 2026 |
| Grant / award Prepayment Warrant (right to buy) | 7,516 | $1.50 | — | — | Jan 23, 2026 |
Insider filings reported around the same time
Other companies whose most recent Form 4 was filed closest to AURX's (Oct 6, 2026).
Frequently asked about AURX insider activity
How many insiders bought AURX stock in these Form 4 filings?
1 distinct insider at Nuo Therapeutics, Inc. reported 2 open-market purchases (Form 4 code P) of AURX shares between Jun 2, 2026 and Oct 6, 2026, the most recent filed by David Emerson Jorden (CEO/CFO) on Aug 28, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Who filed the most recent Form 4 for AURX?
The most recent Form 4 on this page was filed by Scott M. Pittman (Director, 10% owner) on Oct 6, 2026, reporting 2 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.
What was the largest open-market AURX insider purchase shown?
The largest open-market purchase among the filings shown was 7,984 AURX shares at $1.09 (about $8,695) by David Emerson Jorden (CEO/CFO) on Aug 28, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.
Do the recent AURX insider purchases have the Form 4 10b5-1 box checked?
No. All 2 AURX open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: David Emerson Jorden (CEO/CFO) on Aug 28, 2026, 7,984 shares.
New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.
Get insider alerts for AURX — and your whole portfolio
Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy
This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.
Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.